Balance Sheet Components (Tables)

9 Months Ended

Sep. 30, 2017

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Cash and cash equivalents consisted of the following (in thousands):

	September 30, 2017		December 31, 2016
Cash	$	104,875	$	79,239
Money market funds		546,498		94,543
Total cash and cash equivalents	$	651,373	$	173,782

Summary of Amortized Cost, Gross Unrealized Holding Gains or Losses, and Fair Value of Available-for-Sale Investments

All investments are classified as available-for-sale. The amortized cost, gross unrealized holding gains or losses, and fair value of the Company’s available-for-sale investments by major investments type are summarized in the tables below (in thousands):

	September 30, 2017
	Amortized Cost		Gross Unrealized Holding Gains		Gross Unrealized Holding Losses			Fair Value
Corporate bonds	$	75,826	$	62	$	(16	)	$	75,872
Certificate of deposits		1,036		—		—			1,036
Bond and mutual funds		17,182		1,069		—			18,251
Equity investments		126		81		—			207
Total investments	$	94,170	$	1,212	$	(16	)	$	95,366

	December 31, 2016
	Amortized Cost		Gross Unrealized Holding Gains		Gross Unrealized Holding Losses			Fair Value
Corporate bonds	$	126,550	$	182	$	(49	)	$	126,683
Certificate of deposits		1,037		—		—			1,037
Bond and mutual funds		22,305		157		—			22,462
Equity investments		125		100		—			225
Total investments	$	150,017	$	439	$	(49	)	$	150,407

Schedule of Accrued Liabilities

Accrued liabilities consisted of the following (in thousands):

	September 30, 2017		December 31, 2016
Preclinical and clinical trial accruals	$	26,989	$	29,550
Payroll and related accruals		14,654		14,232
Professional services		2,144		1,252
Other		10,330		5,880
Total accrued liabilities	$	54,117	$	50,914